Kintara Therapeutics Inc ends fiscal third quarter with cash and cash equivalents of about $15.7 million
Kintara Therapeutics ends fiscal 3Q with cash and cash equivalents of about $15.7M The capital runway is expected to be sufficient to fund the company's planned operations to the second quarter of calendar year 2022 Kintara achieved the healthy cash stockpile primarily due to the exercise of warrants as well as operational and resource synergies realized through the Adgero Biopharmaceuticals merger in August 2020 Kintara Therapeutics Inc (NASDAQ:KTRA), which is focused on the development of new solid tumor cancer therapies, said it closed its fiscal third quarter with cash and cas...